Pru p 3-specific B-cell receptors and antibodies (Pru p 3 BCR/Ab)

Pru p 3-specific B-cell receptors (BCRs) and antibodies are the primary mediators of the allergic immune response to peach (Prunus persica) (UniProt: P81402). Pru p 3 is a non-specific lipid transfer protein (nsLTP) and is recognized as the major allergen in peach, particularly in Mediterranean populations (Diaz-Perales et al., 2003, PubMed: 12847107). These BCRs and antibodies, specifically of the IgE isotype, bind to Pru p 3, triggering mast cell and basophil degranulation, which leads to symptoms ranging from oral allergy syndrome to systemic anaphylaxis (Garcia-Casado et al., 2003, PubMed: 12688627). Conversely, the induction of Pru p 3-specific IgG4 antibodies is associated with the development of clinical tolerance and is a key goal of therapeutic intervention (Tordesillas et al., 2014, PubMed: 24460479). Therapeutic strategies targeting these molecules include allergen-specific immunotherapy (AIT), which aims to shift the B-cell response from IgE to IgG4 production, and monoclonal antibodies like omalizumab that neutralize circulating IgE. Understanding the repertoire and affinity of these receptors is crucial for developing more effective and safer treatments for peach-induced food allergy and the broader LTP syndrome (Gomez et al., 2015, PubMed: 25617752).

Other names

Anti-Pru p 3 antibodiesPru p 3-specific IgEPru p 3-specific IgG4Pru p 3-specific B-cell receptorPeach nsLTP-specific antibodies

Allergen-specific immunotherapy (AIT) induces immune deviation and the production of blocking IgG4 antibodies; IgE-targeted monoclonal antibodies neutralize circulating IgE to prevent mast cell/basophil activation; B-cell targeted therapies aim to deplete or modulate allergen-specific B-cell populations.